GlassScriptPhysician profile
Kimberly Heckert
NPI 1912127945
$118,582.44
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $5,720 · 2021: $21K · 2022: $56K · 2023: $34K · 2024: $38.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,992 · Honoraria: $5,680 · Travel and Lodging: $2,261 · Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,992.15 |
| Honoraria | $5,680.00 |
| Travel and Lodging | $2,261.41 |
| Food and Beverage | $834.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $57,585.04 | 2019-2023 | Dysport |
| Abbvie INC. | $25,496.15 | 2022-2024 | |
| Allergan, INC. | $20,885.47 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $13,293.96 | 2021-2023 | Xeomin |
| Merz North America, INC. | $818.67 | 2019-2020 | |
| Piramal Critical Care | $201.25 | 2019-2020 | |
| Medtronic USA, INC. | $152.94 | 2019 | |
| Saol Therapeutics INC. | $148.96 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Heckert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.